Healthcare / Pharmaceutical RetailersTaipei Exchange
$72.50
+1.00 (+1.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $746.6M · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10.9B
P/E
18.6x
↓EV/EBITDA
9.8x
↓ROE
15.3%
↑Gross Margin
28.7%
↓Debt/Equity
1.80
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.1%
FCF CAGR
-4.8%
FCF margin
4.2%
FCF / Net income
1.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $18.90B · net income $600.4M · FCF $787.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $18.90B | $18.90B | $17.27B | $16.14B | $14.56B |
| Net Income | $600.4M | $600.4M | $680.8M | $666.0M | $700.1M |
| EBITDA | $1.71B | $1.71B | $1.71B | $1.60B | $1.54B |
| EPS | 3.89 | 3.89 | 4.51 | 4.41 | 4.70 |
| Gross Margin | 28.7% | 28.7% | 28.0% | 27.8% | 27.5% |
| Operating Margin | 3.6% | 3.6% | 4.6% | 5.0% | 5.9% |
| Net Margin | 3.2% | 3.2% | 3.9% | 4.1% | 4.8% |
| Balance Sheet | |||||
| Debt/Equity | 1.80 | 1.80 | 1.67 | 1.57 | 2.03 |
| Current Ratio | 1.48 | 1.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $787.0M | $787.0M | $746.6M | $564.0M | $910.9M |
| Returns | |||||
| ROE | 15.3% | 15.3% | 18.9% | 20.3% | 26.9% |
| Valuation | |||||
| P/E | 18.64 | 18.64 | 28.36 | 58.70 | 40.06 |
| EV/EBITDA | 9.77 | 9.77 | 13.91 | 26.89 | 20.22 |
| P/B | 2.92 | 2.92 | 5.46 | 12.20 | 10.85 |
| Growth & Yield | |||||
| Revenue Growth | 9.4% | 9.4% | 7.0% | 10.8% | — |
| EPS Growth | -13.7% | -13.7% | 2.3% | -6.2% | — |
| Dividend Yield | 4.1% | 4.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
18.3%
EPS terminal req.
$6.43
Spread vs growth
-32.0%
5Y implied EPS CAGR
14.9%
EPS terminal req.
$7.78
Spread vs growth
-28.6%
10Y implied EPS CAGR
12.4%
EPS terminal req.
$12.54
Spread vs growth
-26.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-44.9%
Start / end P/E
31.5x → 18.6x
EPS bridge
4.51 → 3.89
Residual
+5.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.